1.. Background
==============

Pleomorphic lobular carcinoma *in situ* (PLCIS) has only recently been identified as a distinct pathological entity. The first mention of this lesion was in an unindexed case report by Frost *et al* ([@b1-ol-0-0-5331]) in 1996. It has been characterised as an aggressive subtype of classic lobular carcinoma *in situ* (CLCIS). However there is yet to be a consensus among clinicians regarding the optimal treatment of this disease. As recently as 2013 a survey presented in the San Antonio Breast Cancer Symposium demonstrated that there were significant differences in opinion among breast surgeons regarding the optimal excision margins required to adequately treat PLCIS to prevent recurrences in the future ([@b2-ol-0-0-5331]).

In this article, the literature available with regards to this disease were reviewed, including the evidence that distinguishes it from other neoplasms of the breast and the results of the significant clinical studies which have looked into this disease were collated and summarised. Specifically, the risk of concomitant invasive disease or ductal carcinoma *in situ* (DCIS) if PLCIS is found on core needle biopsy (CNB) was determined and the evidence regarding the risk of recurrence in relation to surgical margins and adjuvant therapy was collated.

For the purposes of this systematic review, MedLine, PubMed, the WHO International Clinical Trial Registry Platform and Google Scholar were searched using the following keywords: 'pleomorphic lobular carcinoma *in situ'*, 'pleomorphic lobular carcinoma *in situ*' and 'PLCIS'. Further articles were identified by manual search through the references in previous reviews and studies ([@b3-ol-0-0-5331],[@b4-ol-0-0-5331]).

2.. CLCIS
=========

CLCIS has long been associated with an increased risk of carcinoma. However, in a seminal study in 1978, it was observed that the disease was frequently bilateral and too extensive for surgical excision. Also, it was noted that the invasive disease associated with CLCIS was often invasive ductal carcinoma (IDC) rather than lobular carcinoma ([@b5-ol-0-0-5331]). On the basis of these observations, CLCIS is regarded to be a marker of increased risk of invasive disease rather than a precursor of invasive disease ([@b6-ol-0-0-5331]). It is associated with a risk of invasive breast cancer over 10 years of at least 7.1%. Currently, patients with CLCIS are offered surveillance with regular physical examination and imaging rather than surgical excision ([@b7-ol-0-0-5331]).

Notably, a recent study suggests that in some instances, CLCIS cells may be clonally related to subsequent invasive lobular carcinoma (ILC), which may suggest that CLCIS may serve as a precursor to invasive disease ([@b8-ol-0-0-5331]).

3.. PLCIS
=========

PLCIS was initially described by Frost *et al* ([@b1-ol-0-0-5331]), who described the pathology in the context of a 78 years old woman with an ill-defined mass in the right breast and corresponding calcification on a recent mammogram. The lesion was identified by needle localisation and a biopsy was performed followed by wide local excision and radiotherapy. The lesion was grossly characterised as 'ill defined, multifocal and difficult to measure'. Frost *et al* ([@b1-ol-0-0-5331]) described the microscopic appearance of the cells as large cells with abundant eosinophilic cytoplasm with irregular nuclei with prominent single or multiple nucleoli. The cells extended into the ducts in a pagetoid fashion and filled the duct lumen with tightly packed cells that lacked cohesion. On immunohistochemistry the cells tested positive for gross cystic disease fluid protein 15 (GCDFP 15) and the c-erB-2 oncogene ([@b1-ol-0-0-5331]). PLCIS has also been referred to as 'florid' lobular carcinoma *in situ*, and is clinically and radiologically similar to ductal carcinoma *in situ* ([@b9-ol-0-0-5331]).

In the original description by Frost *et al*, PLCIS was characterised as a hormone receptor negative lesion, in which oestrogen and progesterone receptors were not detected (ER-/PR-) ([@b1-ol-0-0-5331]), as illustrated in [Fig. 1](#f1-ol-0-0-5331){ref-type="fig"}. Since then it has been determined that PLCIS is often a strongly Her2 positive lesion (Her2+), as illustrated in [Fig. 2](#f2-ol-0-0-5331){ref-type="fig"}. An additional recent study noted significant Her2 overexpression and amplification and speculated that this may be involved in the pathogenesis of PLCIS ([@b10-ol-0-0-5331]). This is in contrast to CLCIS, which is commonly a hormone receptor positive and Her2 negative lesion (ER+/PR+/Her2-) ([@b11-ol-0-0-5331],[@b12-ol-0-0-5331]). Androgen receptor expression is similar in both PLCIS and CLCIS ([@b13-ol-0-0-5331]). These distinctions have profound implications in terms of prognosis and significantly limit the potential options available for the adjuvant therapy of PLCIS.

It is well recognised that the differentiation of PLCIS from DCIS, on cytological findings alone may be difficult. It has been found that in common with CLCIS and in contrast to DCIS, PLCIS is characterised by a loss of heterozygosity for the E-Cadherin gene, as illustrated in [Fig. 3](#f3-ol-0-0-5331){ref-type="fig"}. This is a characteristic it shares with CLCIS which may indicate a clonal relationship ([@b14-ol-0-0-5331]).

However, it has long been noted that unlike CLCIS, PLCIS may be frequently associated with invasive disease and has more aggressive course ([@b4-ol-0-0-5331],[@b9-ol-0-0-5331]). PLCIS is considered to be a precursor of invasive disease rather than a marker of increased risk like CLCIS. This is borne out by similarities in biomarkers of synchronous PLCIS and pleomorphic invasive lobular carcinoma (PILC). PLCIS is characterised by increased expression of Ki67 compared to CLCIS, which indicates a high cell turnover. These observations suggest that this may be a radiosensitive lesion unlike LCIS ([@b12-ol-0-0-5331]).

This early characterisation of PLCIS as a precursor to invasion more akin to DCIS, however, was based on impressions gleaned from several histological series earlier in the previous decade ([@b15-ol-0-0-5331],[@b16-ol-0-0-5331]). Data, albeit retrospective, regarding actual recurrence rates after excision and the presence of concomitant invasive disease have only recently become available. This evidence is reviewed in the following sections.

4.. The incidence of concomitant invasive disease with an initial diagnosis of PLCIS
====================================================================================

Following the search of the aforementioned medical databases and perusing the citations used in previous articles, 10 case series were identified in which the diagnosis of PLCIS was made on CNB. A total of 121 such patients were recorded in these 10 studies ([Table I](#tI-ol-0-0-5331){ref-type="table"}) ([@b17-ol-0-0-5331]--[@b25-ol-0-0-5331]).

While case reports were excluded, any patients who formed a part of a larger series in view of the rarity of this condition were included. In all these cases, the patients underwent a core needle biopsy that returned a diagnosis of PLCIS, either alone or in conjunction with another finding such as DCIS, CLCIS or invasion. Furthermore, these patients underwent surgical excision and the authors of these studies reported the final pathological diagnosis.

Of these 121 patients, 81 were recorded to have PLCIS alone on CNB. Of the remainder, 30 exhibited invasion or microinvasion and 7 possessed DCIS. A total of 93 of the patients had wide local excisions (WLE), 3 had diagnostic excisional biopsies and 23 patients had mastectomies.

After final histopathology of the surgical specimen only 33% (n=40) of the total were determined to not have concurrent disease. Of the remainder, 40.5% of the cases reported some form of invasive disease, predominantly invasive lobular carcinoma. Other invasive carcinomas reported were invasive ductal carcinoma and additional instances of lobular microinvasion. In addition, 16% (n=19) of the cases were reported to have concurrent DCIS. These results are in keeping with previous results from case series and systematic reviews. However, it must be noted that all the data in question was collected retrospectively and would be prone to the biases and confounding factors inherent to such data.

5.. The effect of surgical margins and adjuvant therapy on recurrence rates
===========================================================================

The question of the risk of recurrence following excision of PLCIS is understandably a question of great interest to clinicians. It has long been understood that the clinical history of PLCIS is distinct from that of CLCIS, with behaviour more consistent with a precursor of invasive disease rather than a marker of increased risk. The present review of the literature since the identification of PLCIS as a distinct pathological diagnosis identified four studies that comment upon excision margins and recurrence of the disease ([Table II](#tII-ol-0-0-5331){ref-type="table"}).

The first study reported in the literature is that of Downs-Kelly *et al* ([@b26-ol-0-0-5331]) in 2011, which reported on 26 patients who underwent resection for PLCIS and also received adjuvant chemo and radiotherapy. These patients were identified retrospectively from the hospital database. Of these, 20 had PLCIS on pathology, a further 6 patients with an invasive component were included if they were classified as suspicious for microinvasion or invasion measuring between 1--5 cm and \>1 cm from the resection margins. The basis for these criteria is unclear. Furthermore, the patients were stratified according to their resection margins. Of these patients, 10 patients did not receive any adjuvant therapy, 7 received chemotherapy only and 3 received radiotherapy only. The remainder received both chemo- and radiotherapy. Again, the basis for this was not clarified in the text by the authors. This group of patients was followed up for a mean of 46 months. In this time, only one recurrence was reported at 19 months, which was PLCIS (3.8%). The authors remark that the patient in question had disease at the margin and had only received chemotherapy. On the basis of this data the authors recommend treating PLCIS as one would treat DCIS with excision margins of at least 2 mm and to consider adjuvant therapy ([@b26-ol-0-0-5331]).

The second study in question is that of Fasola *et al* ([@b19-ol-0-0-5331]) of which only an abstract is publically available. Out of 34 patients, all of whom underwent wide local excision, the authors report three local recurrences over a 5-year period. In their cohort, the authors noted PLCIS alone had a higher local recurrence rate compared to PLCIS associated with invasion. It was also noted that the cases which developed local recurrences following excision of PLCIS alone did not receive surgical re-excision or adjuvant therapy and the surgical margins were within 1 mm of the lesion ([@b19-ol-0-0-5331]).

Khoury *et al* ([@b27-ol-0-0-5331]) report on a case series of 47 patients diagnosed with PLCIS followed up over a 12-year period. Within this group, the authors selected 31 patients with PCLIS in order to study the risk of local recurrence following excision. The median follow-up period was 55.6 months, 6 local recurrences were reported of which 4 were invasive carcinoma and 2 were PLCIS only. None of these patients received radiotherapy. Also of note is that of the 11 patients who received hormonal therapy, 3 developed local recurrences. Khoury *et al* ([@b27-ol-0-0-5331]) identified a statistically significant correlation between tumour recurrence and patient age in which the mean age for recurrence was 52.5 years compared to 60.6 years for those who did not develop recurrences ([@b27-ol-0-0-5331]).

The most recent study to comment on recurrence rates was that of Flanagan *et al* ([@b28-ol-0-0-5331]) who reported on a case series of 23 patients who were diagnosed with PLCIS. Of these 23 patients, 2 had adequate margins on the excisional biopsy and required no further intervention, while 16 underwent wide local excision and 5 had mastectomies. However even among the 16 who had WLE there was difficulty in getting clear margins and were subjected to re-excisions. Eventually another 7 patients required mastectomies as well. Over the 4 years of follow-up, the authors reported no instances of local recurrence. However, they also emphasize that the pursuit of clear margins in the case of PLCIS precluded successful breast conservation. Therefore, the authors urge caution in the aggressive treatment of PLCIS with regards to margins ([@b28-ol-0-0-5331]).

The retrospective nature of the data and the inconsistency in reporting of surgical margins preclude the formulation of an objective recommendation concerning the same. All of the authors appear to agree that clear margins will lead to lower recurrence rates. However, Flanagan *et al* ([@b28-ol-0-0-5331]) report that this may not always be possible or feasible.

Similarly, there is a lack of consistency in the adjuvant therapy given to patients, with little clarity in the literature concerning the criteria used to guide such decisions. It would be desirable to form a consensus with regards to the place of adjuvant therapy with regards to the treatment of PLCIS. As observed above, the numbers of patients in these studies are not sufficient to lead to any solid conclusions. However, Downs-Kelley *et al* ([@b26-ol-0-0-5331]) and Khoury *et al* ([@b27-ol-0-0-5331]) and indicated that radiotherapy led to a lower recurrence rate in their case series. Furthermore, Khoury *et al* ([@b27-ol-0-0-5331]) noted that patients on hormone therapy contributed to half of the recurrence cases. This issue may need to be explored in larger well-designed prospective studies.

6.. Conclusion
==============

The literature regarding PLCIS is relatively novel. In view of the rarity of this condition, usable evidence is accumulating slowly. Consequently, it may not always be possible to formulate recommendations based on the appropriate evidence. However, on the basis of the observed behaviour of the disease in retrospective studies, it would not be unreasonable to characterise PLCIS as significant risk factors for concomitant carcinoma with a significant risk of recurrence after excision. This is the position of the National Cancer Comprehensive Network (NCCN) and NHS breast screening program (NHSBSP) who recommend treating PLCIS similar to DCIS ([@b29-ol-0-0-5331],[@b30-ol-0-0-5331]). However, as evident in more recent studies, such an approach may not be consistent with breast conservation ([@b28-ol-0-0-5331]). This clinical issue warrants investigation in appropriately powered, well-designed, prospective studies for a satisfactory resolution of all concerns.

The present study was funded by the Breast Cancer Hope Foundation (London, UK).

![Estrogen receptor staining in PLCIS. Immunohistochemistry for oestrogen receptor showing weak and variable oestrogen receptor staining in a sample of breast tissue with PLCIS at ×40 magnification. Staining was performed using ER/PR pharmdx kits supplied by Dako UK Ltd, (Ely, UK). PLCIS, pleomorphic lobular carcinoma *in situ*.](ol-12-06-4863-g00){#f1-ol-0-0-5331}

![Her2 staining in PLCIS. Immunohistochemistry for Her2 showing strong positivity in a sample of breast tissue with PLCIS at ×200 magnification. PLCIS, pleomorphic lobular carcinoma *in situ*.](ol-12-06-4863-g01){#f2-ol-0-0-5331}

![E-cadherin staining in PLCIS. Immunohistochemistry showing loss of e-cadherin staining in a sample of breast tissue with PLCIS at ×200 magnification. PLCIS, pleomorphic lobular carcinoma *in situ*.](ol-12-06-4863-g02){#f3-ol-0-0-5331}

![Core biopsy showing expanded acini filled with a pleomorphic proliferation of cells. Haematoxylin and eosin, ×40 magnification.](ol-12-06-4863-g03){#f4-ol-0-0-5331}

![Higher power showing the pleomorphism of the cells but also lobular features with intracytoplasmic lumina. Haematoxylin and eosin, ×200 magnification.](ol-12-06-4863-g04){#f5-ol-0-0-5331}

###### 

Collation of retrospective studies reporting the incidence of concomitant invasive disease or DCIS in the patients with a CNB positive for PLCIS.

  Study                                                            N      Diagnosis on CNB        Surgical procedure   PLCIS alone on surgical specimen   Concurrent DCIS or invasion on surgical specimen   Concurrent DCIS (%)   Concurrent invasive cancer (%)   Ref
  ---------------------------------------------------------------- ------ ----------------------- -------------------- ---------------------------------- -------------------------------------------------- --------------------- -------------------------------- ----------------------
  Carder *et al*^[a](#tfn1-ol-0-0-5331){ref-type="table-fn"}^        10   PLCIS: 5                DB: 2 WLE:             1                                1 micro ILC,                                       0                     30                               ([@b17-ol-0-0-5331])
                                                                          PLCIS                                                                                                                                                                                     
                                                                          with microinvasion: 2   6 Mx:2                                                  2 ILC                                                                                                     
                                                                          PLCIS with CLCIS: 3                                                                                                                                                                       
  Chivikula *et al*^[b](#tfn2-ol-0-0-5331){ref-type="table-fn"}^     12   PLCIS: 12               DB: 1 WLE:             7                                1 DCIS+                                            8.30                  25                               ([@b18-ol-0-0-5331])
                                                                                                  9 Mx: 2                                                 ILC, 2 ILC                                                                                                
  Fasola *et al*                                                     34   PLCIS: 13               WLE: 20                4                                9 PLCIS+DCIS,                                      26.47                 61.76                            ([@b19-ol-0-0-5331])
                                                                          PLCIS 'with             Mx: 142                                                 6 PLCIS+IDC,                                                                                              
                                                                          invasion': 21                                                                   15 PLCIS+ILC                                                                                              
  Morris *et al*                                                     17   PLCIS: 3 PLCIS          WLE:17                 3                                3 PLCIS+DCIS,                                      17.65                 17.65                            ([@b20-ol-0-0-5331])
                                                                          +DCIS: 7                                                                        11 PLCIS+ILC                                                                                              
                                                                          PLCIS+IC: 7                                                                                                                                                                               
  Niell *et al*                                                      5    PLCIS: 5                WLE: 5                 1                                1 PLCIS+ILC,                                       40                    60                               ([@b21-ol-0-0-5331])
                                                                                                                                                          1 LCIS+ILC, 1                                                                                             
                                                                                                                                                          DCIS+IDC, 1 DCIS                                                                                          
  Lavoure *et al*^[c](#tfn3-ol-0-0-5331){ref-type="table-fn"}^       10   PLCIS: 10               WLE: 10                7                                3 PLCIS+ILC                                        0                     30                               ([@b22-ol-0-0-5331])
  Georgian-Smith *et al*                                             5    PLCIS: 5                WLE: 5                 3                                2 PLCIS+ILC                                        --                    40                               ([@b23-ol-0-0-5331])
  Mahoney *et al*                                                    2    PLCIS: 2                WLE: 2                 1                                1 PLCIS+ILC                                        --                    50                               ([@b24-ol-0-0-5331])
  Purdie *et al*^[e](#tfn5-ol-0-0-5331){ref-type="table-fn"}^        3    PLCIS: 3                WLE: 3                 1                                1 ILC, 1 PLCIS+ILC                                 --                    66                               ([@b25-ol-0-0-5331])
  Flanagan *et al*^[d](#tfn4-ol-0-0-5331){ref-type="table-fn"}^      23   PLCIS: 23               WLE: 16              12                                 5 ILC, 2 ILC+                                      17                    30                               ([@b28-ol-0-0-5331])
                                                                                                  Mx: 5                                                   IDC, 1 DCIS,                                                                                              
                                                                                                                                                          3 PLCIS+DCIS                                                                                              
  Total                                                            121                                                                                                                                       15.70                 40.5                             

3 of the 5 PLCIS were initially reported as high grade DCIS.

9 WLE (1 lumpectomy, 8 segmental mastectomies) 2 Mx (1 Simple Mx, 1 Bilateral Mx).

2 of the 7 cases of pure PLCIS were extensive and required Mx.

17 were initially diagnosed by needle biopsy while 6 diagnosed by excisional biopsy. In total 12 of the patients had to undergo Mx.

The PLCIS+ILC was noted as 'microinvasion'. N, number of patients; CNB, core needle biopsy; PLCIS, pleomorphic carcinoma *in situ*; CLCIS, classic carcinoma *in situ*; DCIS, ductal carcinoma *in situ*; IC, invasive carcinoma; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DB, diagnostic biopsy; WLE, wide local excision; Mx, mastectomy.

###### 

Summary of retrospective studies reporting local recurrence rates after excision of PLCIS.

  Study                                                           Median follow-up (months)                            Median age   N    Surgical margins   Adjuvant therapy                                     Histology of recurrences   Time to recurrence (months)   LRR (%)   Ref
  --------------------------------------------------------------- ---------------------------------------------------- ------------ ---- ------------------ ---------------------------------------------------- -------------------------- ----------------------------- --------- ----------------------
  Fasola *et al*^[b](#tfn7-ol-0-0-5331){ref-type="table-fn"}^     57                                                   55           34   ≤1 mm: 34          RT+/−                                                Not                        Not                           8.82      ([@b19-ol-0-0-5331])
                                                                  (12--163)                                            (41--84)                             CT: 16                                               stated                     stated                                  
                                                                                                                                                            HT: 9^[c](#tfn8-ol-0-0-5331){ref-type="table-fn"}^                                                                      
  Downs-Kelly *et al*                                             32.5                                                 59.5         26   At margin: 6       No Rx: 10                                            PLCIS: 1                   18                            3.84      ([@b26-ol-0-0-5331])
                                                                  (4--108)                                             (35--76)            \<1 mm: 7        CRT: 6                                                                                                                  
                                                                                                                                         1.1--2 mm: 4       CT: 6                                                                                                                   
                                                                                                                                           \>2.1 mm: 9      RT: 4                                                                                                                   
  Khoury *et al*^[a](#tfn6-ol-0-0-5331){ref-type="table-fn"}^     55.6                                                 59.5         31   Not stated         RT: 3                                                PLCIS: 2                   Not                           12.70     ([@b27-ol-0-0-5331])
                                                                  (1.6--112)                                           (40--88)                             HT: 11                                               Invasion: 4                stated                                  
  Flanagan *et al*^[d](#tfn9-ol-0-0-5331){ref-type="table-fn"}^   49.2^[e](#tfn10-ol-0-0-5331){ref-type="table-fn"}^   55           18   At margin: 14      RT: 1                                                None                       --                            0         ([@b28-ol-0-0-5331])
                                                                  (5.7--115)                                           (36--70)          1.1--2 mm: 4       HT: 3                                                                                                                   

The authors excluded patients with a previous history of breast cancer or a concurrent diagnosis of invasive cancer.

Details for margins not given: 'Recurrences had margins of \<1 mm'

PLCIS alone cases.

The authors excluded 28 patients with concomitant breast cancer. Of the 23 remaining, 5 underwent mastectomy and have been removed from the analysis.

Mean. N, number of patients; LRR, local recurrence rate; Rx, therapy; CT, chemotherapy; RT, radiotherapy; CRT, chemo-radiotherapy; HT, hormone therapy.
